Trial · NCT00604214
Results by group64
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 64
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| 28-Day All-Cause Mortality | Drotrecogin Alfa (Activated) | 26.4 | percentage of participants | ||
| 28-Day All-Cause Mortality | Placebo | 24.2 | percentage of participants | ||
| 28-Day All-Cause Mortality in Participants With Severe Protein C Deficiency | Drotrecogin Alfa (Activated) | 28.7 | percentage of participants | ||
| 28-Day All-Cause Mortality in Participants With Severe Protein C Deficiency | Placebo | 30.8 | percentage of participants | ||
| Average Cardiovascular Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28 | Drotrecogin Alfa (Activated) | 1.92 | Standard Deviation 1.31 | units on a scale | |
| Average Cardiovascular Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28 | Placebo | 1.84 | Standard Deviation 1.31 | units on a scale | |
| Average Respiratory Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28 | Drotrecogin Alfa (Activated) | 2.31 | Standard Deviation 1.05 | units on a scale | |
| Average Respiratory Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28 | Placebo | 2.29 | Standard Deviation 1.05 | units on a scale | |
| Average Renal Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28 | Drotrecogin Alfa (Activated) | 1.38 | Standard Deviation 1.42 | units on a scale | |
| Average Renal Sequential Organ Failure Assessment (SOFA) Score Day 1 Through Day 28 | Placebo | 1.28 | Standard Deviation 1.40 | units on a scale | |
| 90-Day Mortality | Drotrecogin Alfa (Activated) | 34.1 | percentage of participants | ||
| 90-Day Mortality | Placebo | 32.7 | percentage of participants | ||
| 180-Day Mortality | Drotrecogin Alfa (Activated) | 36.6 | percentage of participants | ||
| 180-Day Mortality | Placebo | 35.9 | percentage of participants | ||
| Median Survival Time | Drotrecogin Alfa (Activated) | NA | Full Range NA to NA | days | |
| Median Survival Time | Placebo | NA | Full Range NA to NA | days | |
| EuroQoL Questionnaire-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) Scores at Baseline, Days 28, 90 and 180 | Drotrecogin Alfa (Activated) | Baseline (n=685, 679) | 54.21 | Standard Deviation 26.99 | units on a scale |
| EuroQoL Questionnaire-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) Scores at Baseline, Days 28, 90 and 180 | Placebo | Baseline (n=685, 679) | 54.37 | Standard Deviation 27.95 | units on a scale |
| EuroQoL Questionnaire-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) Scores at Baseline, Days 28, 90 and 180 | Drotrecogin Alfa (Activated) | Day 28 (n=500, 476) | 54.78 | Standard Deviation 23.46 | units on a scale |
| EuroQoL Questionnaire-5 Dimensions (EQ-5D) Visual Analog Scale (VAS) Scores at Baseline, Days 28, 90 and 180 | Placebo | Day 28 (n=500, 476) | 55.24 | Standard Deviation 22.89 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00604214/results